Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.

Abstract

Because human infections by Scedosporium prolificans are difficult to treat and show a very poor outcome, new therapeutic strategies are needed. Liposomal amphotericin B (LAMB) (40 mg/kg/day) increased significantly the mean survival time in immunosuppressed mice compared with a control group (22.6 vs. 8.8 days). Amphotericin B deoxycholate (1.5 mg/kg/day) and granulocyte colony-stimulating factor (G-CSF) (300 microg/kg/day) were ineffective. The combination of LAMB (40 mg/kg/day) and G-CSF (150 or 300 microg/kg/day) did not improve the results obtained with LAMB alone.

• Authors: Montserrat Ortoneda, Javier Capilla, F Javier Pastor, Carolina Serena, Josep Guarro
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 50 Issue 4 Pg. 247-51 (Dec 2004) ISSN: 0732-8893 [Print] United States
• PMID: 15582297 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Liposomes
• liposomal amphotericin B
• Granulocyte Colony-Stimulating Factor
• Amphotericin B

Topics

• Amphotericin B (administration & dosage, therapeutic use)
• Animals
• Antifungal Agents (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Drug Interactions
• Drug Therapy, Combination
• Granulocyte Colony-Stimulating Factor (administration & dosage, therapeutic use)
• Immunocompromised Host
• Liposomes
• Lymphocyte Count
• Male
• Mice
• Mice, Inbred Strains
• Mycetoma (drug therapy)
• Scedosporium